VYGR
Voyager Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$228.86M
P/E Ratio
—
EPS
$-2.04
Beta
1.38
52W High
$5.55
52W Low
$2.65
50-Day MA
$3.92
200-Day MA
$3.98
Dividend Yield
—
Profit Margin
-296.50%
Forward P/E
8.44
PEG Ratio
0.00
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $40.37M |
| Gross Profit (TTM) | $-91.90M |
| EBITDA | $-124.28M |
| Operating Margin | -172.40% |
| Return on Equity | -48.30% |
| Return on Assets | -24.90% |
| Revenue/Share (TTM) | $0.69 |
| Book Value | $3.32 |
| Price-to-Book | 1.14 |
| Price-to-Sales (TTM) | 5.67 |
| EV/Revenue | 1.559 |
| EV/EBITDA | 2.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 144.30% |
| Shares Outstanding | $59.60M |
| Float | $47.32M |
| % Insiders | 15.35% |
| % Institutions | 59.88% |
Historical Volatility
HV 10-Day
40.22%
HV 20-Day
52.79%
HV 30-Day
80.88%
HV 60-Day
70.67%
HV Rank
79.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($14.89 target)
12
BuyData last updated: 4/14/2026